AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4073085 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin plus gentamicin (600 mg every six hours plus 3 to 5 mg/kg per day)
Number of subjects: 47
Study 30178449 — intervention group
Group type: EXPERIMENTAL
Intervention: RIRS (Retrograde Intrarenal Surgery)
Number of subjects: 60
Study 30178449 — intervention group
Group type: COMPARATOR
Intervention: mini-Percutaneous Nephrolithotomy (mini-PNL)
Number of subjects: 60
Study 30415816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg/2 weeks after 160-mg initial dose)
Number of subjects: 149
Study 30415816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 149
Study 30415816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 26488229 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mL hybrid palm oil daily for 3 months
Number of subjects: 160
Study 26488229 — intervention group
Group type: COMPARATOR
Intervention: 25 mL extra virgin olive oil daily for 3 months
Number of subjects: 160
Study 24536039 — intervention group
Group type: EXPERIMENTAL
Intervention: Barberry (3 capsules daily for 6 weeks)
Number of subjects: 106
Study 24536039 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 capsules daily for 6 weeks)
Number of subjects: 106
Study 22821620 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (10 μg)
Number of subjects: 93
Study 22821620 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (100 μg)
Number of subjects: 93
Study 22821620 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 93
Study 20051221 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil (200 mg once daily)
Number of subjects: 249
Study 20051221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 18197497 — intervention group
Group type: COMPARATOR
Intervention: AQP3 in ascending colon (trial group: 0.905, control group: 0.798)
Number of subjects: 66
Study 18197497 — intervention group
Group type: COMPARATOR
Intervention: AQP9 in ascending colon (trial group: 0.544, control group: 0.543)
Number of subjects: 66
Study 18197497 — intervention group
Group type: COMPARATOR
Intervention: AQP3 in descending colon (trial group: 0.697, control group: 0.701)
Number of subjects: 66
Study 18197497 — intervention group
Group type: COMPARATOR
Intervention: AQP9 in descending colon (trial group: 0.575, control group: 0.732)
Number of subjects: 66
Study 15944884 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibulopathic subjects
Number of subjects: 35
Study 15944884 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 35
Study 12630074 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone and somatomedins
Number of subjects: 0
Study 10073832 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 132
Study 10073832 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 132
Study 10073832 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 132
Study 7491886 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat milk (1.4 g Ca/d)
Number of subjects: 9
Study 7491886 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented low-fat milk (1.4 g Ca/d)
Number of subjects: 9
Study 7491886 — intervention group
Group type: COMPARATOR
Intervention: Soft drink (0.16 g Ca/d)
Number of subjects: 9
Study 1781044 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone scintigraphy and chest X-ray
Number of subjects: 0
Study 1781044 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic use of bone scintigraphy and chest X-ray
Number of subjects: 0
Study 30699971 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g freeze-dried blueberry powder
Number of subjects: 63
Study 30699971 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 63
Study 27659923 — intervention group
Group type: EXPERIMENTAL
Intervention: Active deep brain stimulation (DBS)
Number of subjects: 25
Study 27659923 — intervention group
Group type: COMPARATOR
Intervention: Sham deep brain stimulation (DBS)
Number of subjects: 25
Study 26007261 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention and physical exercise for 12 weeks
Number of subjects: 33
Study 26007261 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention and physical exercise for 12 weeks (Men)
Number of subjects: 33
Study 26007261 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention and physical exercise for 12 weeks (Women)
Number of subjects: 33
Study 26007261 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention and physical exercise for 12 weeks (35-40 years group)
Number of subjects: 33
Study 26007261 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention and physical exercise for 12 weeks (41-50 years group)
Number of subjects: 33
Study 26007261 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention and physical exercise for 12 weeks (51-63 years group)
Number of subjects: 33
Study 26007261 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention and physical exercise for 12 weeks (BMI 20-25)
Number of subjects: 33
Study 26007261 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention and physical exercise for 12 weeks (BMI >25)
Number of subjects: 33
Study 23551992 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolysed guar gum (PHGG), 10 g/d
Number of subjects: 44
Study 23551992 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diet without PHGG)
Number of subjects: 44
Study 21342323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 45
Study 21342323 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CC)
Number of subjects: 45
Study 18986749 — intervention group
Group type: EXPERIMENTAL
Intervention: Laserneedle acupuncture
Number of subjects: 60
Study 18986749 — intervention group
Group type: COMPARATOR
Intervention: Metal needle acupuncture
Number of subjects: 60
Study 17870123 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding exercises with placebo (group A)
Number of subjects: 149
Study 17870123 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding exercises with oxybutynin (group B)
Number of subjects: 149
Study 17870123 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone (group C)
Number of subjects: 149
Study 17870123 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin alone (group D)
Number of subjects: 149
Study 17870123 — intervention group
Group type: COMPARATOR
Intervention: Alarm treatment (controls, group E)
Number of subjects: 149
Study 12027843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bain system + ACD with fresh gas flow 4.4‐6.4 l/min
Number of subjects: 16
Study 12027843 — intervention group
Group type: COMPARATOR
Intervention: Low flow circle system with 1.5 l/min fresh gas flow
Number of subjects: 16
Study 10602894 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibling bone marrow transplantation (BMT)
Number of subjects: 88
Study 10602894 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated donor bone marrow transplantation (BMT)
Number of subjects: 88
Study 10602894 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 88
Study 10602894 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-free survival (DFS) after sibling BMT
Number of subjects: 88
Study 10602894 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-free survival (DFS) after URD BMT
Number of subjects: 88
Study 10602894 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse of CML
Number of subjects: 88
Study 10602894 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant-related mortality
Number of subjects: 88
Study 10602894 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute graft-versus-host disease (GVHD)
Number of subjects: 88
Study 10602894 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic graft-versus-host disease (GVHD)
Number of subjects: 88
Study 7589007 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (Tissucol, 5 ml of 500 IU thrombin) applied in the area of axillary dissection
Number of subjects: 40
Study 7589007 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 40
Study 7589007 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (Tissucol, 5 ml of 500 IU thrombin)
Number of subjects: 40
Study 1939803 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin (Herculite XR, Clearfil Ray Posterior, Visiomolar)
Number of subjects: 56
Study 1939803 — intervention group
Group type: COMPARATOR
Intervention: Amalgam (Tytin)
Number of subjects: 56
Study 6792379 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven days of penicillin V potassium (96 patients)
Number of subjects: 191
Study 6792379 — intervention group
Group type: COMPARATOR
Intervention: Ten days of penicillin V potassium (95 patients)
Number of subjects: 191
Study 31120272 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitor and Accept (MA) mindfulness training
Number of subjects: 0
Study 31120272 — intervention group
Group type: COMPARATOR
Intervention: Monitor Only (MO) mindfulness training
Number of subjects: 0
Study 31120272 — intervention group
Group type: COMPARATOR
Intervention: No Treatment (NT) control
Number of subjects: 0
Study 28232237 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mg of atomoxetine
Number of subjects: 24
Study 25936475 — intervention group
Group type: EXPERIMENTAL
Intervention: TMAC
Number of subjects: 107
Study 25936475 — intervention group
Group type: COMPARATOR
Intervention: MAC
Number of subjects: 107
Study 21878470 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for the A allele of SNP rs821597
Number of subjects: 149
Study 21878470 — intervention group
Group type: EXPERIMENTAL
Intervention: DISC1 haplotypes (rs3738401|rs6675281|rs821597|rs821616|rs967244|rs980989)
Number of subjects: 149
Study 21878470 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype GCGTCG and ACGTTT
Number of subjects: 149
Study 21502621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg/12 h)
Number of subjects: 61
Study 21502621 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg/12 h)
Number of subjects: 61
Study 21502621 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin (400 mg/24 h)
Number of subjects: 61
Study 21502621 — intervention group
Group type: COMPARATOR
Intervention: Standard antituberculosis treatment alone (Control)
Number of subjects: 61
Study 18573590 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ‐IO
Number of subjects: 84
Study 18573590 — intervention group
Group type: COMPARATOR
Intervention: MAN‐IO
Number of subjects: 84
Study 17168934 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre posts (Snowpost) luted with adhesive composite resin cement (Panavia F)
Number of subjects: 50
Study 17168934 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium alloy posts (Parapost) luted with resin cement
Number of subjects: 50
Study 17168934 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium alloy posts with glass-ionomer cement (Fuji I)
Number of subjects: 50
Study 17168934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast post-and-cores luted with resin cement
Number of subjects: 50
Study 17168934 — intervention group
Group type: COMPARATOR
Intervention: Cast post-and-cores with glass-ionomer cement
Number of subjects: 50
Study 15294406 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously prepared saline solutions
Number of subjects: 672
Study 15294406 — intervention group
Group type: COMPARATOR
Intervention: Saline solutions exposed for 24, 48, or 72 hours
Number of subjects: 672
Study 10395855 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines (ACVs) - full strength, one-third strength, one-tenth strength
Number of subjects: 481
Study 10395855 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines (ACVs)
Number of subjects: 481
Study 10395855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study 7744190 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline
Number of subjects: 12
Study 7744190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2286480 — intervention group
Group type: EXPERIMENTAL
Intervention: Jogging 2 h/week for 4 months
Number of subjects: 61
Study 2286480 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 7356349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal inoculation of 10(8) to 10(9) organisms of Staphylococcus aureus 502A
Number of subjects: 32
Study 7356349 — intervention group
Group type: COMPARATOR
Intervention: Sterile broth (control)
Number of subjects: 32
Study 31120898 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented motivational interviewing (MI)
Number of subjects: 175
Study 31120898 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 175
Study 31120898 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented MI
Number of subjects: 175
Study 29145771 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin/chitosan gel (10 mg/mL) applied three times/day for 7 days
Number of subjects: 0
Study 29145771 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin suspension
Number of subjects: 0
Study 29145771 — intervention group
Group type: COMPARATOR
Intervention: Chitosan gel
Number of subjects: 0
Study 29145771 — intervention group
Group type: COMPARATOR
Intervention: Petroleum gel
Number of subjects: 0
Study 26703921 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-focused behavioural intervention during PR (3 months) and follow-up support (3 months)
Number of subjects: 32
Study 24090342 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-meter walk test (10MWT)
Number of subjects: 85
Study 24090342 — intervention group
Group type: EXPERIMENTAL
Intervention: five times sit-to-stand test (FTSST)
Number of subjects: 85
Study 24090342 — intervention group
Group type: EXPERIMENTAL
Intervention: timed up and go test (TUGT)
Number of subjects: 85
Study 24090342 — intervention group
Group type: EXPERIMENTAL
Intervention: cane
Number of subjects: 85
Study 24090342 — intervention group
Group type: COMPARATOR
Intervention: walker
Number of subjects: 85
Study 24090342 — intervention group
Group type: COMPARATOR
Intervention: crutches
Number of subjects: 85
Study 23113482 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg intravenous infusion at baseline and 12 months)
Number of subjects: 1199
Study 23113482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1199
Study 23113482 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 1199
Study 20166859 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone patch (TTP, 300 microg/day)
Number of subjects: 272
Study 20166859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 17395523 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐DAY ACUVUE (1DA)
Number of subjects: 282
Study 17395523 — intervention group
Group type: COMPARATOR
Intervention: FOCUS DAILIES (FD)
Number of subjects: 282
Study 16287890 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to quit
Number of subjects: 4207
Study 16287890 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to quit inquiry
Number of subjects: 4207
Study 16287890 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance in quitting
Number of subjects: 4207
Study 16287890 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up offer
Number of subjects: 4207
Study 16287890 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with care
Number of subjects: 4207
Study 12122534 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufflation of 10 ml/kg air into the stomach
Number of subjects: 78
Study 12122534 — intervention group
Group type: COMPARATOR
Intervention: Control group (no air insufflation)
Number of subjects: 78
Study 10443966 — intervention group
Group type: COMPARATOR
Intervention: n‐3 fatty acid‐deficient, corn oil‐based formula (CO)
Number of subjects: 108
Study 10443966 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 108
Study 10443966 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha‐linolenic acid-enriched, soy oil-based formula
Number of subjects: 108
Study 10443966 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental formula enriched with soy and marine oils
Number of subjects: 108
Study 10443966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheek cell DHA at 36 weeks
Number of subjects: 108
Study 10443966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheek cell DHA at 57 weeks
Number of subjects: 108
Study 8703663 — intervention group
Group type: EXPERIMENTAL
Intervention: rilmenidine 1-2 mg day-1
Number of subjects: 12
Study 8703663 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 50-100 mg day-1
Number of subjects: 12
Study 30714794 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment
Number of subjects: 107
Study 27540039 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal temperature probe with insulated thermocouples (Group 1)
Number of subjects: 80
Study 27540039 — intervention group
Group type: COMPARATOR
Intervention: No oesophageal temperature monitoring (Group 2)
Number of subjects: 80
Study 25545453 — intervention group
Group type: EXPERIMENTAL
Intervention: Almost continuous skin-to-skin contact (SSC)
Number of subjects: 37
Study 25545453 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 37
Study 23261789 — intervention group
Group type: EXPERIMENTAL
Intervention: Late preterm infants (LPI)
Number of subjects: 123
Study 23261789 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants with less negative parenting
Number of subjects: 123
Study 23261789 — intervention group
Group type: EXPERIMENTAL
Intervention: Very preterm infants (VPI)
Number of subjects: 123
Study 21988726 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphasis Change (EC)
Number of subjects: 60
Study 21988726 — intervention group
Group type: COMPARATOR
Intervention: Active Control (AC)
Number of subjects: 60
Study 21988726 — intervention group
Group type: COMPARATOR
Intervention: Passive Control (PC)
Number of subjects: 60
Study 19954718 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (60 mg/day, three times per week) for 1 year
Number of subjects: 47
Study 19954718 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 47
Study 17300851 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m2) plus Vinorelbine (25 mg/m2) bi-weekly
Number of subjects: 46
Study 15167676 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg until the day before surgery)
Number of subjects: 20
Study 15167676 — intervention group
Group type: COMPARATOR
Intervention: Control (no aspirin or discontinued >5 days before surgery)
Number of subjects: 20
Study 11316974 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg/day of orally administered flutamide combined with leuprorelin (initiated on the day of leuprorelin injection)
Number of subjects: 26
Study 11316974 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg/day of orally administered flutamide combined with leuprorelin (initiated 1 week before leuprorelin injection)
Number of subjects: 26
Study 11316974 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg/day of orally administered flutamide combined with leuprorelin (initiated 2 weeks before leuprorelin injection)
Number of subjects: 26
Study 11316974 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg/day of orally administered flutamide combined with leuprorelin (initiated 4 weeks before leuprorelin injection)
Number of subjects: 26
Study 11316974 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection of 3.75 mg leuprorelin acetate depot alone
Number of subjects: 26
Study 9396403 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF during CT only (n = 64)
Number of subjects: 253
Study 9396403 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF during and after CT (n = 66)
Number of subjects: 253
Study 9396403 — intervention group
Group type: COMPARATOR
Intervention: No GM-CSF (n = 63)
Number of subjects: 253
Study 9396403 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF after CT only (n = 60)
Number of subjects: 253
Study 9396403 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF during CT
Number of subjects: 253
Study 9396403 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF after CT
Number of subjects: 253
Study 7943592 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic octreotide acetate, 150 micrograms to 300 micrograms per day, beginning on day 1
Number of subjects: 28
Study 7943592 — intervention group
Group type: COMPARATOR
Intervention: No octreotide treatment (21 patients)
Number of subjects: 28
Study 3581491 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg betahistine
Number of subjects: 10
Study 3581491 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg betahistine
Number of subjects: 10
Study 3581491 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 mg betahistine
Number of subjects: 10
Study 31789094 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical abuse
Number of subjects: 427
Study 31789094 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional abuse
Number of subjects: 427
Study 31789094 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual abuse
Number of subjects: 427
Study 31789094 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvictimization
Number of subjects: 427
Study 31789094 — intervention group
Group type: EXPERIMENTAL
Intervention: Beliefs supporting aggression
Number of subjects: 427
Study 31789094 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-being and life satisfaction
Number of subjects: 427
Study 29466079 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery (50% maximal aerobic speed)
Number of subjects: 8
Study 29466079 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 8
Study 26916927 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized physical therapy exercise intervention
Number of subjects: 126
Study 26916927 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study 24343267 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivorship care plans (SCPs)
Number of subjects: 38